Literature DB >> 19875272

Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats.

Yong Kee Choi1, Taylor Moran-Gates, Matthew P Gardner, Frank I Tarazi.   

Abstract

Risperidone is an atypical antipsychotic drug that is widely prescribed to young patients with different psychotic disorders. The long-term effects of this antipsychotic agent on neuronal receptors in developing brain remain unclear and require further investigation. In this study, we examined the effects of long-term treatment of risperidone on two serotonin receptor subtypes in brain regions of juvenile rat. Levels of 5-HT(1A) and 5-HT(2A) receptors in forebrain regions of juvenile rats were quantified after 3 weeks of treatment with three different doses of risperidone (0.3, 1.0 and 3.0mg/kg). Findings were compared to previously reported changes in 5-HT receptors after risperidone treatment (3.0mg/kg) in adult rat brain. The three doses of risperidone selectively and dose-dependently increased levels of 5-HT(1A) receptors in medial-prefrontal and dorsolateral-frontal cortices of juvenile animals. The higher doses (1.0 and 3.0mg/kg) of risperidone also increased 5-HT(1A) receptor binding in hippocampal CA(1) region of juvenile but not adult rats. In contrast, the three doses of risperidone significantly reduced 5-HT(2A) labeling in medial-prefrontal and dorsolateral-frontal cortices in juvenile as well as in adult animals in an equipotent fashion. 5-HT(1A) and 5-HT(2A) receptors in other forebrain regions were not altered by repeated risperidone treatment. These findings indicate that there are differential effects of risperidone on 5-HT(1A) and 5-HT(2A) receptors in juvenile animals, and that the 5-HT system in developing animals is more sensitive than adults to the long-term effects of risperidone. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19875272      PMCID: PMC2819571          DOI: 10.1016/j.euroneuro.2009.09.002

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  51 in total

1.  Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy.

Authors:  Shitij Kapur; Susan C VanderSpek; Barbara A Brownlee; Jose N Nobrega
Journal:  J Pharmacol Exp Ther       Date:  2003-02-20       Impact factor: 4.030

2.  Childhood schizophrenia. A review and comparison with adult-onset schizophrenia.

Authors:  J H Beitchman
Journal:  Psychiatr Clin North Am       Date:  1985-12

3.  [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role.

Authors:  J E Leysen; C J Niemegeers; J M Van Nueten; P M Laduron
Journal:  Mol Pharmacol       Date:  1982-03       Impact factor: 4.436

4.  Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions.

Authors:  Frank I Tarazi; Kehong Zhang; Ross J Baldessarini
Journal:  Psychopharmacology (Berl)       Date:  2002-04-04       Impact factor: 4.530

5.  Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors.

Authors:  A Pazos; J M Palacios
Journal:  Brain Res       Date:  1985-11-04       Impact factor: 3.252

Review 6.  Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses.

Authors:  Brian J McConville; Michael T Sorter
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

Review 7.  Atypical antipsychotics in the treatment of children and adolescents: clinical applications.

Authors:  Robert L Findling; Nora K McNamara
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

8.  Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia.

Authors:  Jean A Frazier; Louise Glassner Cohen; Leslie Jacobsen; Dale Grothe; James Flood; Ross J Baldessarini; Stephen Piscitelli; Grace S Kim; Judith L Rapoport
Journal:  J Clin Psychopharmacol       Date:  2003-02       Impact factor: 3.153

9.  Risperidone in children with autism and serious behavioral problems.

Authors:  James T McCracken; James McGough; Bhavik Shah; Pegeen Cronin; Daniel Hong; Michael G Aman; L Eugene Arnold; Ronald Lindsay; Patricia Nash; Jill Hollway; Christopher J McDougle; David Posey; Naomi Swiezy; Arlene Kohn; Lawrence Scahill; Andres Martin; Kathleen Koenig; Fred Volkmar; Deirdre Carroll; Allison Lancor; Elaine Tierney; Jaswinder Ghuman; Nilda M Gonzalez; Marco Grados; Benedetto Vitiello; Louise Ritz; Mark Davies; James Robinson; Don McMahon
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

10.  The 5-HT2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism.

Authors:  Guy A Higgins; Michel Enderlin; Marie Haman; Paul J Fletcher
Journal:  Psychopharmacology (Berl)       Date:  2003-08-07       Impact factor: 4.530

View more
  17 in total

1.  Early-life risperidone enhances locomotor responses to amphetamine during adulthood.

Authors:  Bobbie Lee Stubbeman; Clifford J Brown; Justin R Yates; Mark E Bardgett
Journal:  Eur J Pharmacol       Date:  2017-07-14       Impact factor: 4.432

2.  Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.

Authors:  Shinnyi Chou; Sean Jones; Ming Li
Journal:  Brain Res       Date:  2015-06-03       Impact factor: 3.252

3.  Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia.

Authors:  Yael Piontkewitz; Michal Arad; Ina Weiner
Journal:  Schizophr Bull       Date:  2010-05-03       Impact factor: 9.306

4.  Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model.

Authors:  Qing Shu; Gang Hu; Ming Li
Journal:  J Psychopharmacol       Date:  2013-11-20       Impact factor: 4.153

5.  Delayed yet persistent effects of daily risperidone on activity in developing rats.

Authors:  Rachel M Stevens; Matthew A Gannon; Molly S Griffith; Mark E Bardgett
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

6.  Asenapine sensitization from adolescence to adulthood and its potential molecular basis.

Authors:  Qing Shu; Rongyin Qin; Yingzhu Chen; Gang Hu; Ming Li
Journal:  Behav Brain Res       Date:  2014-08-02       Impact factor: 3.332

7.  Long-lasting sensitization induced by repeated risperidone treatment in adolescent Sprague-Dawley rats: a possible D2 receptor mediated phenomenon?

Authors:  Jing Qiao; Jun Gao; Qing Shu; Qinglin Zhang; Gang Hu; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2013-12-21       Impact factor: 4.530

8.  Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism.

Authors:  Jun Gao; Ming Li
Journal:  Behav Brain Res       Date:  2013-10-05       Impact factor: 3.332

9.  Long-term impacts of adolescent risperidone treatment on behavioral responsiveness to olanzapine and clozapine in adulthood.

Authors:  Jing Qiao; Qinglin Zhang; Ming Li
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-10-16       Impact factor: 5.067

10.  Adult rats treated with risperidone during development are hyperactive.

Authors:  Mark E Bardgett; Julie M Franks-Henry; Kristin R Colemire; Kathleen R Juneau; Rachel M Stevens; Cecile A Marczinski; Molly S Griffith
Journal:  Exp Clin Psychopharmacol       Date:  2013-06       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.